ticlopidine has been researched along with Vascular Diseases in 48 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 9.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials." | 5.51 | Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 5.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "In the overall population, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in comparison to aspirin monotherapy reduced the relative risk of total stroke by 20% (risk ratio [RR], 0." | 4.90 | Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. ( Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M, 2014) |
| "To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin." | 4.84 | Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008) |
| " We review what we consider to be the top 12 advances in this field: the discovery of nitric oxide, the metabolic syndrome, new thrombophilic disorders, therapeutic angiogenesis, endoluminal treatment of chronic venous disease, and a variety of drugs, including sildenafil, cilostazol, low-molecular-weight heparins, oral direct thrombin inhibitors, clopidogrel, statins, and angiotensin-converting enzyme inhibitors and angiotensin-receptor blocking agents." | 4.82 | The top 12 advances in vascular medicine. ( Beckman, JA; Jaff, MR; Jang, J; Olin, JW; Rooke, T, 2004) |
| " Carriers of this polymorphism have a higher incidence of stent thrombosis and cardiovascular death, whilst on the thienopyridine clopidogrel." | 3.76 | Prasugrel, Māori, and personalised medicine in New Zealand. ( Gladding, P; Webster, M; White, H, 2010) |
| "Previous DAPT studies consistently demonstrated greater efficacy but an increased risk of bleeding compared with aspirin alone in patients with acute coronary syndromes or undergoing percutaneous coronary intervention." | 3.76 | Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. ( Bhatt, DL; Boden, WE; Flather, MD, 2010) |
| "Patients with Type 2 diabetes carry an equivalent cardiovascular risk to that of a non-diabetic individual who has already experienced a coronary event." | 2.47 | Management of type-2 diabetes with anti-platelet therapies: special reference to aspirin. ( Rao, GH, 2011) |
| "to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials." | 1.51 | Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "Aspirin was both less expensive and more effective than clopidogrel in post-myocardial infarction patients." | 1.32 | Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. ( Owens, DK; Schleinitz, MD; Weiss, JP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.25) | 18.7374 |
| 1990's | 6 (12.50) | 18.2507 |
| 2000's | 21 (43.75) | 29.6817 |
| 2010's | 18 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiran, A | 1 |
| Adawi, S | 1 |
| Rubinshtein, R | 1 |
| Bardicef, M | 1 |
| Gutterman, E | 1 |
| Jeong, HG | 1 |
| Yoon, JS | 1 |
| Lee, J | 1 |
| Bae, HJ | 1 |
| Gouya, G | 1 |
| Arrich, J | 1 |
| Wolzt, M | 1 |
| Huber, K | 1 |
| Verheugt, FW | 1 |
| Gurbel, PA | 1 |
| Pirker-Kees, A | 1 |
| Siller-Matula, JM | 1 |
| Smith, L | 1 |
| Cruickshank, R | 1 |
| Beattie, D | 1 |
| Burkes, M | 1 |
| Abdullah, AS | 1 |
| Ibrahim, H | 1 |
| Kiernan, TJ | 1 |
| Wu, S | 1 |
| Liu, W | 1 |
| Zhou, Y | 1 |
| Wonnacott, D | 1 |
| Berringer, R | 1 |
| Sacco, RL | 1 |
| Diener, HC | 2 |
| Yusuf, S | 4 |
| Cotton, D | 2 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 1 |
| Martin, RH | 2 |
| Albers, GW | 2 |
| Bath, P | 1 |
| Bornstein, N | 1 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Cunha, L | 1 |
| Dahlöf, B | 1 |
| De Keyser, J | 1 |
| Donnan, GA | 2 |
| Estol, C | 1 |
| Gorelick, P | 1 |
| Gu, V | 1 |
| Hermansson, K | 1 |
| Hilbrich, L | 1 |
| Kaste, M | 1 |
| Lu, C | 1 |
| Machnig, T | 1 |
| Pais, P | 1 |
| Roberts, R | 1 |
| Skvortsova, V | 1 |
| Teal, P | 1 |
| Toni, D | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Yoon, BW | 1 |
| Connolly, SJ | 1 |
| Pogue, J | 1 |
| Hart, RG | 1 |
| Hohnloser, SH | 1 |
| Pfeffer, M | 1 |
| Chrolavicius, S | 1 |
| Chua, D | 1 |
| Legal, M | 1 |
| Shalansky, SJ | 1 |
| McClung, JA | 1 |
| Kruger, AL | 1 |
| Ferraris, A | 1 |
| Vanella, L | 1 |
| Tsenovoy, P | 1 |
| Weiss, MB | 1 |
| Abraham, NG | 1 |
| Gladding, P | 1 |
| White, H | 1 |
| Webster, M | 1 |
| Berger, PB | 1 |
| Bhatt, DL | 2 |
| Fuster, V | 1 |
| Steg, PG | 1 |
| Fox, KA | 1 |
| Shao, M | 1 |
| Brennan, DM | 1 |
| Hacke, W | 1 |
| Montalescot, G | 1 |
| Steinhubl, SR | 2 |
| Topol, EJ | 1 |
| Boden, WE | 1 |
| Flather, MD | 1 |
| Bonello, L | 1 |
| Harhouri, K | 1 |
| Sabatier, F | 1 |
| Camoin-Jau, L | 1 |
| Arnaud, L | 1 |
| Baumstarck-Barrau, K | 1 |
| Ait-Mokhtar, O | 1 |
| Roubille, F | 1 |
| Piot, C | 1 |
| Lesavre, N | 1 |
| Paganelli, F | 1 |
| Dignat-George, F | 1 |
| Rudez, G | 1 |
| Duckers, HJ | 1 |
| Simoons, ML | 1 |
| Rao, GH | 1 |
| Stewart, K | 1 |
| Walters, M | 1 |
| Dawson, J | 1 |
| Ovbiagele, B | 1 |
| Vinisko, R | 1 |
| Bath, PM | 1 |
| Douglas, IJ | 1 |
| Evans, SJ | 1 |
| Hingorani, AD | 1 |
| Grosso, AM | 1 |
| Timmis, A | 1 |
| Hemingway, H | 1 |
| Smeeth, L | 1 |
| Reinhart, WH | 1 |
| Rodgers, JE | 1 |
| Schleinitz, MD | 1 |
| Weiss, JP | 1 |
| Owens, DK | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Olin, JW | 2 |
| Jang, J | 1 |
| Jaff, MR | 1 |
| Beckman, JA | 1 |
| Rooke, T | 1 |
| Karnon, J | 1 |
| Brennan, A | 1 |
| Pandor, A | 1 |
| Fowkes, G | 1 |
| Lee, A | 1 |
| Gray, D | 1 |
| Coshall, C | 1 |
| Nicholls, C | 1 |
| Akehurst, R | 1 |
| Hansen, DB | 1 |
| Bavry, AA | 1 |
| Lincoff, AM | 1 |
| Mani, H | 1 |
| Lindhoff-Last, E | 1 |
| Mattle, H | 1 |
| Niederkorn, K | 1 |
| Serebruany, VL | 1 |
| Malinin, AI | 1 |
| Atar, D | 1 |
| Hanley, DF | 1 |
| Bowry, AD | 1 |
| Brookhart, MA | 1 |
| Choudhry, NK | 2 |
| Kapoor, JR | 1 |
| Vyas, S | 1 |
| Roberti, I | 1 |
| McCarthy, C | 1 |
| Levin, R | 1 |
| Avorn, J | 1 |
| Hermosillo, AJ | 1 |
| Spinler, SA | 1 |
| Mazoyer, E | 1 |
| Ripoll, L | 1 |
| Boisseau, MR | 1 |
| Drouet, L | 1 |
| Ferguson, JJ | 1 |
| Gonzalez, ER | 1 |
| Kannel, WB | 1 |
| Raps, EC | 1 |
| Tanaka, T | 1 |
| Takei, M | 1 |
| Fukuta, Y | 1 |
| Higashino, R | 1 |
| Fukuda, Y | 1 |
| Nomura, Y | 1 |
| Ito, S | 1 |
| Tamaki, H | 1 |
| Kurimoto, T | 1 |
| Suzuki, Y | 1 |
| D'Sa, S | 1 |
| Machin, SJ | 1 |
| Aronow, WS | 1 |
| Guilmot, JL | 1 |
| Diot, E | 1 |
| Gruel, Y | 1 |
| Frangos, SG | 1 |
| Chen, AH | 1 |
| Sumpio, B | 1 |
| Mehta, SR | 1 |
| Strano, A | 1 |
| Davì, G | 1 |
| Cannizzaro, S | 1 |
| Giubilato, A | 1 |
| Harker, LA | 1 |
| Teraoka, S | 1 |
| Takahashi, K | 1 |
| Toma, H | 1 |
| Sanaka, T | 1 |
| Yamaguchi, Y | 1 |
| Tanabe, K | 1 |
| Sato, H | 1 |
| Kawaguchi, H | 1 |
| Oba, S | 1 |
| Nakajima, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
16 reviews available for ticlopidine and Vascular Diseases
| Article | Year |
|---|---|
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studie | 2014 |
Spontaneous coronary artery dissection: Case report and review of the literature.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Adult; Aspirin; Atorvastatin; Clopi | 2016 |
Management of type-2 diabetes with anti-platelet therapies: special reference to aspirin.
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; | 2011 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi | 2003 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
The top 12 advances in vascular medicine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Clopidogrel; Factor V; Heparin, Low-Molecular- | 2004 |
Is clopidogrel cardiovascular medicine's double-edged sword?
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Therapy, Combination; | 2006 |
[Resistance to acetylsalicylic acid and clopidogrel: current status].
Topics: Aspirin; Clopidogrel; Drug Monitoring; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggre | 2006 |
Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Platelet Aggregation Inhibito | 2008 |
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com | 2008 |
How does ticlopidine treatment lower plasma fibrinogen?
Topics: Blood Viscosity; Clinical Trials as Topic; Fibrinogen; Humans; Prospective Studies; Randomized Contr | 1994 |
Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; | 1999 |
Vascular drugs in the new millennium.
Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa | 2000 |
Role of ticlopidine for prevention of stroke.
Topics: Cerebrovascular Disorders; Drug Combinations; Humans; Risk Factors; Ticlopidine; Vascular Diseases | 1992 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
6 trials available for ticlopidine and Vascular Diseases
| Article | Year |
|---|---|
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema | 2010 |
Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Endothelial Cells; En | 2010 |
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibit | 2000 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
27 other studies available for ticlopidine and Vascular Diseases
| Article | Year |
|---|---|
Non-invasive management of post-partum spontaneous left main coronary artery dissection using cardiac computed tomography angiography.
Topics: Adult; Aspirin; Bisoprolol; Cesarean Section; Clopidogrel; Computed Tomography Angiography; Conserva | 2017 |
Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study.
Topics: Aged; Cohort Studies; Drug Combinations; Female; Ginkgo biloba; Hemorrhage; Humans; Incidence; Male; | 2019 |
Tips for GP trainees working in vascular surgery.
Topics: Anticholesteremic Agents; Aspirin; Blood Pressure; Clinical Competence; Clopidogrel; Education, Medi | 2014 |
Spontaneous coronary artery dissection: a complete resolution with medical treatment.
Topics: Adult; Aspirin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Fibrinolytic Agents; H | 2014 |
Spontaneous coronary artery dissection in the presence of myocardial bridge causing myocardial infarction: an insight into mechanism.
Topics: Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female; | 2016 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I | 2009 |
Usefulness of clopidogrel to protect against diabetes-induced vascular damage.
Topics: Adult; Aged; Cell Count; Clopidogrel; Diabetes Complications; Diabetes Mellitus, Type 2; Endothelial | 2010 |
Prasugrel, Māori, and personalised medicine in New Zealand.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genet | 2010 |
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 2010 |
Clopidogrel and endothelial injury after percutaneous coronary interventions: beyond the antiplatelet effects.
Topics: Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Endothelium, Vascular; Humans; Myocard | 2010 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90).
Topics: Aspirin; Clopidogrel; Constriction, Pathologic; Delayed-Action Preparations; Dipyridamole; Drugs, Ge | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.
Topics: Aspirin; Clopidogrel; Cohort Studies; Data Collection; Drug Interactions; Humans; Multivariate Analy | 2012 |
Platelets in vascular disease.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Hemostasis; Humans; Plaque, Atherosclerotic; | 2013 |
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Fibrinolytic Agents; Humans; Markov Chains; Middle Aged | 2004 |
Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat | 2005 |
[Clopidogrel versus acetylsalicylic acid in the secondary prophylaxis of vascular diseases. A commentary on the report of the Institute for Quality and Efficiency in the Health Service].
Topics: Academies and Institutes; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; | 2007 |
Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema | 2007 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
May-Thurner syndrome in a pediatric renal transplant recipient--case report and literature review.
Topics: Adolescent; Clopidogrel; Creatinine; Edema; Female; Graft Survival; Humans; Iliac Vein; Kidney Disea | 2008 |
The economic consequences of non-evidence-based clopidogrel use.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Cohort Studies; Evidence-Based Medic | 2008 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa | 1998 |
Arachidonic acid-induced hind limb gangrene: a new experimental rat model of peripheral vascular disease.
Topics: Animals; Arachidonic Acid; Aspirin; Disease Models, Animal; Disease Progression; Drug Evaluation, Pr | 1999 |
Clopidogrel: a novel antiplatelet agent.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre | 1999 |
[Contribution of platelet aggregation inhibitors in the prevention of complications of atherothrombosis].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Factor | 2000 |
Application of prostacyclin analogue and thromboxane synthetase inhibitor to chronic vascular rejection after kidney transplantation.
Topics: Acrylates; Chronic Disease; Epoprostenol; Graft Rejection; Humans; Kidney Transplantation; Methacryl | 1987 |